扶正抗癌方联合DC方案对非小细胞肺癌患者肿瘤标志物水平、免疫功能及毒副反应发生情况的影响  

Effects of Fuzheng Kang'ai recipe combined with DC regimen on tumor markers levels,immune function and occurrence of toxic and side effects in patients with non-small cell lung cancer

作　　者：王虹伊 赵钦 陆军 杨洋 郭巧宁 WANG Hongyi;ZHAO Qin;LU Jun;YANG Yang;GUO Qiaoning(Xi'an International Medical Center Hospital,Xi'an 710100,China)

机构地区：[1]西安国际医学中心医院,陕西西安710100

出　　处：《临床医学研究与实践》2022年第21期139-142,共4页Clinical Research and Practice

基　　金：西安国际医学中心医院院级课题项目(No.2020QN018)。

摘　　要：目的探讨扶正抗癌方联合DC方案治疗非小细胞肺癌(NSCLC)的临床效果,以为临床治疗方式的合理选择提供借鉴。方法将2019年1月至2021年1月我院收治的80例NSCLC患者根据治疗方式不同分为对照组和试验组,各40例。对照组给予DC方案,试验组在对照组基础上给予扶正抗癌方。比较两组的临床疗效、肿瘤标志物[癌胚抗原(CEA)、细胞角蛋白19片段抗原21-1(CYFRA21-1)、血管内皮生长因子(VEGF)及硫氧还蛋白还原酶1(TrxR1)]水平、免疫功能[白细胞分化抗原3阳性(CD3^(+))、白细胞分化抗原4阳性(CD4^(+))、白细胞分化抗原8阳性(CD8^(+))、CD4^(+)/CD8^(+)]、毒副反应发生情况、体力状况及生活质量。结果试验组的疾病控制率高于对照组,差异具有统计学意义(P<0.05)。治疗后,两组的CEA、CYFRA21-1、VEGF、TrxR1水平均降低,且试验组低于对照组,差异具有统计学意义(P<0.05)。治疗后,试验组的CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组,CD8^(+)低于对照组,差异具有统计学意义(P<0.05)。试验组的骨髓抑制、胃肠道反应、肝肾功能异常及其他毒副反应总发生率低于对照组,差异具有统计学意义(P<0.05)。治疗后,两组的KPS、QLQ-LC13评分均升高,且试验组高于对照组,差异具有统计学意义(P<0.05)。结论扶正抗癌方联合DC方案治疗NSCLC能够提高抗肿瘤效果,降低肿瘤标志物水平,改善免疫失衡状态,减轻毒副反应,提高患者生活质量,值得临床推广和应用。Objective To investigate the clinical effect of Fuzheng Kang'ai recipe combined with DC regimen in the treatment of non-small cell lung cancer(NSCLC),so as to provide reference for the rational choice of clinical treatment methods.Methods A total of 80 patients with NSCLC admitted in our hospital from January 2019 to January 2021 were divided into control group and experimental group according to different treatment methods,with 40 cases in each group.The control group was given DC regimen,and the experimental group was given Fuzheng Kang'ai recipe on the basis of the control group.The clinical efficacy,tumor markers[carcinoembryonic antigen(CEA),cytokeratin 19 fragments antigen 21-1(CYFRA21-1),vascular endothelial growth factor(VEGF)and thioredoxin reductase(TrxR1)]levels,immune function[cluster of differentiation 3 positive(CD3^(+)),cluster of differentiation 4 positive(CD4^(+)),cluster of differentiation 8 positive(CD8^(+)),and CD4^(+)/CD8^(+)],occurrence of toxic and side effects,performance status and quality of life were compared between the two groups.Results The disease control rate of the experimental group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of CEA,CYFRA21-1,VEGF and TrxR1 in the two groups decreased,and those in the experimental group were lower than the control group,the differences were statistically significant(P<0.05).After treatment,the CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in the experimental group were higher than those in the control group,and CD8^(+)was lower than that in the control group,the differences were statistically significant(P<0.05).The total incidences of myelosuppression,gastrointestinal reaction,abnormal liver and kidney function and other toxic and side effects in the experimental group were lower than those in the control group,and the differences were statistically significant(P<0.05).After treatment,KPS and QLQ-LC13 scores of the two groups increased,and those of the experimental group were hig

关 键 词：扶正抗癌方 非小细胞肺癌 肿瘤标志物 免疫功能 毒副反应 生活质量 

分 类 号：R734.2[医药卫生—肿瘤]